$14.9M capital deployed

28% primary ownership

Sep '11 initial capital deployed

return to top

Why Putney?

Headquartered in Portland, ME, Putney is a rapidly growing pet pharmaceutical company focused on developing high-quality, generic prescription medicines for pets.

Putney’s mission is to provide veterinary practices with FDA-approved veterinary generic medicines that meet pet medical needs and offer cost-effective alternatives for pet owners.

According to IMS Health, 86% of all human prescriptions in the U.S. are filled with a generic, yet very few generics exist for drugs prescribed for pets. Analysis of FDA Center for Veterinary Medicine (“CVM”) approvals reveals that 91% of FDA-approved drugs for pets have no generic equivalent. The overall size of the pet pharmaceutical market is significant. Packaged Facts, in its April 2014 report entitled, “Pet Medications in the U.S.” stated that the U.S. retail sales of pet medications reached $8 billion in 2013 and projected that the market will grow to more than $10 billion in 2018, reflecting a compound annual growth rate of 5%.

In 2014, Putney received FDA CVM approval for four generic prescription medicines for pets, including Putney Carprofen Chewable Tablets (generic of Rimadyl® Chewable Tablets), Putney Dexmedetomidine Hydrochloride (generic of Dexdomitor®), Putney Carprofen Sterile Injectable Solution (generic of Rimadyl® Injectable), and Putney Meloxicam Solution for Injection (generic of Metacam® Solution for Injection). As a result, Putney is the only company selling FDA approved generics for all three dosage forms of carprofen products, and is the only company selling Dexmedetomidine Hydrochloride, the first and only generic of Dexdomitor®.

(Updated as of 12/31/14)